2seventy bio EBIT

The latest EBIT for TSVT is $-60M as of March 2025. That compares with $-190M in the prior-year period — up 68.9% year over year. That is below the sector sector average of $-6.4M. Investors often review this figure alongside 2seventy bio's historical trend and sector peers before judging valuation or financial health.

Over the past year, TSVT's EBIT moved from $-190M to $-60M — a 68.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in 2seventy bio's operating scale or balance-sheet position.

Against its sector companies, TSVT currently prints $-60M for EBIT, while the sector average sits near $-6.4M. That is roughly 835.8% below the sector mean. Large gaps often invite a closer look at 2seventy bio's growth, margins, and balance sheet.

A EBIT figure of $-60M for TSVT is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $-6.4M. Explore the charts below for those layers of context.

After noting TSVT's EBIT ($-60M), review year-over-year change from $-190M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.